Xilio reports preliminary data from Phase I solid tumors therapy trial

Xilio Therapeutics has reported preliminary data from its Phase I clinical trial of XTX101 for the treatment of advanced solid tumours.

XTX101 is an investigational tumour-activated, Fc-enhanced anti-CTLA-4 which depletes regulatory T cells upon activation in the tumour microenvironment.